SBIR-STTR Award

This Phase I STTR proposal seeks funding to transfer technology from the Foundation for Applied Molecular Evolution (nonprofit) to GenoMechanix (for-profit) relating to a strategy for doing "sequencing by synthesis". This strategy involves the incorporation, in a template-directed polymerization step, of a nucleoside triphosphate having its 3'-hydroxyl group transiently blocked by an amino group, and carrying a fluorescent tag of distinctive color. The amine blocking group is small, removable under aqueous conditions, and likely to be accepted by natural DNA polymerases, especially if their performance is enhanced via directed evolution. The Phase 1 objective is to identify a procedure for optimally removing the 3'-OH blocking group under conditions where the duplex between the primer and the template remains, and the DNA is essentially under graded. To this end, reductive, oxidative, and beta-elimination reagents will be examined. The Phase 1 milestone will be passed if the removal meets the specifications (>99% complete in < 15 minutes, aqueous conditions, < 0.5 %DNA degradation). The Phase 2 project will then develop a platform for sequencing by synthesis. A working sequencing-by-synthesis system that permits parallel (for example, a 100 x 100 array) sequencing would be extremely useful, provided that the reads are >25 nucleotides in length). This would represent a major new project direction for GenoMechanix, but within its mission of providing reagents and tools for and from genomic sciences. They would also help meet the goal of the National Institutes of Health, including the goal of reducing the cost of sequencing whole genomes by one or more orders of magnitude, enhancing biomedical research at greatly reduced cost

Sequencing during synthesis (SdS) is an architecture for massively parallel DNA sequencing that has the strong potential of lowering the cost of sequencing enough to allow individuals access to their own genetic heritage as a way of personalizing their medical care. Thus far, however, higher-throughput next-generation sequencing systems are relatively expensive, have relatively long run times and produce relatively short reads, thereby limiting their use for diagnostic applications. This proposal will support the transfer of reagent technology from the Foundation for Applied Molecular Evolution (FfAME) to Intelligent Bio-Systems (IBS), where it will be optimized to yield, at the end of the Phase 2 period, a high-performance prototype instrument that better meets the needs of both the research and healthcare communities.

Public Health Relevance:
Sequencing during synthesis (SdS) is an architecture for doing massively parallel DNA sequencing that has the strong potential of lowering the cost of sequencing enough to allow individuals access to their own genetic heritage as a way of personalizing their medical care. Intelligent Bio-Systems (IBS) seeks to become the cost and quality leader in this next generation of DNA sequencing technology. This proposal will support the transfer of reagent technology from the Foundation for Applied Molecular Evolution (FfAME) to IBS, where it will be optimized for the IBS instrument to yield, at the end of the Phase 2 period, a commercial instrument.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.